Drug intelligence / Profile preview

peginterferon alfa-2a + ribavirin + tacrolimus

Development stage: Unknown
Lead developer: Roche
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
Administration: Subcutaneous, Oral

Overview

This combination regimen, studied by The University of Texas Health Science Center, Houston, consists of peginterferon alfa-2a, ribavirin, and tacrolimus for the treatment of recurrent hepatitis C in liver transplant recipients. Peginterferon alfa-2a is a long-acting cytokine that binds to the IFNAR1/IFNAR2 receptors to stimulate antiviral, antiproliferative, and immunomodulatory effects. Ribavirin is a guanosine analog that inhibits viral replication through multiple mechanisms, including inosine-5'-monophosphate dehydrogenase (IMPDH) inhibition and viral RNA polymerase interference. Tacrolimus is a calcineurin inhibitor that binds to FKBP12 to inhibit T-lymphocyte activation, serving as the primary immunosuppressant to prevent graft rejection during antiviral therapy. This specific Phase 4 protocol investigated the feasibility of preemptive treatment to prevent the progression of HCV-related liver damage post-transplantation while maintaining tacrolimus monotherapy for immunosuppression.

Brand names: PegasysCopegusPrograf
Other names: peginterferon alfa-2a + ribavirin + tacrolimus combination therapy

Targets

CN (Calcineurin)IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)

Beyond the preview

Go deeper on peginterferon alfa-2a + ribavirin + tacrolimus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on peginterferon alfa-2a + ribavirin + tacrolimus.

Explore the full profile